IDYA · NASDAQ
IDEAYA Biosciences (IDYA) Stock Price & Fundamentals
IDEAYA Biosciences (IDYA) closed at $599.00 on Oct 9, 2026, up 0.95% from the previous close of $593.38.
Share price, past year
1Y +29.01%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $599.00 |
| Sep 30, 2026 | $592.35 |
| Aug 31, 2026 | $577.56 |
| Jul 31, 2026 | $572.79 |
| Jun 30, 2026 | $511.83 |
| May 29, 2026 | $500.64 |
| Apr 30, 2026 | $473.53 |
| Mar 31, 2026 | $468.50 |
| Feb 27, 2026 | $473.45 |
| Jan 30, 2026 | $517.85 |
| Dec 31, 2025 | $507.05 |
| Nov 28, 2025 | $494.60 |
| Oct 31, 2025 | $464.78 |
Key statistics
- Market cap
- $57.73B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.91
- Revenue (TTM)
- —
- Net income (TTM)
- −$175.02M
- Shares outstanding
- 96.4M
- Dividend yield
- —
- 52-week range
- $449.28 – $600.41
IDEAYA Biosciences's market cap is $57.73B, based on a share price of $599.00 and 96.4M shares outstanding as of Jun 30, 2026.
Financials
IDEAYA Biosciences reported revenue of $218.71M for fiscal 2025, up 3,024.43% from fiscal 2024.
IDEAYA Biosciences reported a net loss of $113.70M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $218.71M | +3,024.4% | −$113.70M | −52.0% | −$1.28 | −$73.47M |
| FY2024ended Dec 31, 2024 | $7.00M | −70.1% | −$274.48M | −3,921.1% | −$3.36 | −$251.44M |
| FY2023ended Dec 31, 2023 | $23.39M | −54.1% | −$112.96M | −483.1% | −$1.96 | −$117.59M |
| FY2022ended Dec 31, 2022 | $50.93M | +82.3% | −$58.66M | −115.2% | −$1.42 | −$90.62M |
| FY2021ended Dec 31, 2021 | $27.94M | +43.0% | −$49.76M | −178.1% | −$1.41 | −$58.42M |
| FY2020ended Dec 31, 2020 | $19.54M | — | −$34.50M | −176.6% | −$1.40 | $54.97M |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$41.98M | — | −$3.36 | −$40.67M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $8.86M | −$112.45M | −$1.22 |
| Q1 FY2026ended Mar 31, 2026 | $6.56M | −$98.54M | −$1.11 |
| Q3 FY2025ended Sep 30, 2025 | $207.83M | $119.24M | $1.33 |
| Q4 FY2024ended Dec 31, 2024 | $7.00M | −$130.31M | −$1.55 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$51.82M | −$0.60 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
| Q1 FY2024ended Mar 31, 2024 | $0.00 | — | — |
| Q4 FY2023ended Dec 31, 2023 | $3.92M | — | — |
Company profile
- Name
- IDEAYA Biosciences, Inc.
- Ticker
- IDYA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 5000 Shoreline Ct, Suite 300, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001676725
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jun 23, 2026
- Jun 10, 2026
- Jun 3, 2026
- Jun 1, 2026
- May 5, 2026
- May 5, 2026
Frequently asked questions
What is IDEAYA Biosciences's stock price?
IDEAYA Biosciences (IDYA) closed at $599.00 on Oct 9, 2026, up 0.95% from the previous close of $593.38.
What is IDEAYA Biosciences's market cap?
IDEAYA Biosciences's market cap is $57.73B, based on a share price of $599.00 and 96.4M shares outstanding as of Jun 30, 2026.
How much revenue does IDEAYA Biosciences make?
IDEAYA Biosciences reported revenue of $218.71M for fiscal 2025, up 3,024.43% from fiscal 2024.
Does IDEAYA Biosciences pay a dividend?
IDEAYA Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from IDEAYA Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures